go-v.orgdoi

Elucidating the role of Cystatin C in Alzheimer's disease pathology

Kristen A. Marcellus · container not stated · 2014

  • DOI 10.82308/26328
  • Publisher OpenAlex
  • Type dissertation
  • Issued 2014

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

· OpenAlex · dissertation · 2014

Abstract

Alzheimer's disease (AD) is the most prevalent form of dementia and is a progressive neurodegenerative disease, characterized by extracellular amyloid-beta plaques, intracellular neurofibrillary tangles, and neuronal death. In Alzheimer's disease patients, atrophy occurs in regions of the brain involved in learning and memory, resulting in cognitive impairment. Late-onset AD (LOAD), 90-95% of cases, is a multifactorial disease, as seen by the many morphological changes in the brain. Familial AD is caused by mutations in the APP or presenilin (PSEN1 and PSEN2) genes. However, the cause of LOAD remains unknown.

Several susceptibility genes have been identified and amongst these genes is cystatin C (CysC), a cysteine protease inhibitor. Meta-analysis studies have characterized CysC as a potential risk factor for LOAD. An allelic variant, allele B, has an alanine to threonine substitution in the signal peptide, which results in the switch of a nonpolar amino acid to a polar one, which alters the hydrophobicity profile of the signal sequence, causing impaired secretion of CysC. Furthermore, studies have revealed extremely CysC immunoreactive neurons, as well as activated glia in the cerebral cortex of AD patients.

Also, in the most susceptible neurons, CysC protein accumulates in intracellular vesicles. In the brains of patients with AD, neuronal concentrations of CysC are elevated and co-localize with Aβ, depositing in extracellular Aβ plaques. CysC has been implicated in many other processes, including apoptosis regulation, cell proliferation, mitogenic activity, and cell survival/prevention of cell death. The identification and characterization of novel disease mechanisms and treatment targets are important in the field of AD in order to better understand disease etiology and aid the development of potential therapeutics.

We hypothesize that CysC is involved in AD pathology and plays a key role in the progression of the disease. The objective of this study is to characterize the effect of CysC on the pathological hallmarks of AD. The results demonstrate that cystatin C is upregulated in the neuronal areas most susceptible to AD pathogenesis, the frontal cortex and the hippocampus of the 3xTg-AD mouse model. Furthermore, CysC causes apoptosis and does not attenuate APP toxicity in neuroblastoma cells. Interestingly, CysC results in the hyperphosphorylation of tau at the PHF-1 site in vitro, which is mediated by GSK3β.

Additionally, Egr-1 regulates CysC in vivo, in both Egr-1 knockout and Egr-1 transgenic mice models. The results suggest that CysC may contribute to the pathology of AD. Further research into the mechanisms of CysC induction of apoptosis and tau phosphorylation may shed light on a possible therapeutic target through the inhibition of CysC.

Open the resolved locator · 10.82308/26328

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 03:45 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://hdl.handle.net/20.500.14905/123324
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.